Edition:
United Kingdom

Abeona Therapeutics Inc (ABEO.OQ)

ABEO.OQ on NASDAQ Stock Exchange Capital Market

10.09USD
3:57pm BST
Change (% chg)

$-0.36 (-3.44%)
Prev Close
$10.45
Open
$10.41
Day's High
$10.41
Day's Low
$10.02
Volume
28,039
Avg. Vol
181,692
52-wk High
$22.00
52-wk Low
$9.68

Chart for

About

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin... (more)

Overall

Beta: 2.29
Market Cap(Mil.): $713.08
Shares Outstanding(Mil.): 40.29
Dividend: --
Yield (%): --

Financials

  ABEO.OQ Industry Sector
P/E (TTM): -- 85.92 33.73
EPS (TTM): -0.60 -- --
ROI: -29.33 0.63 14.31
ROE: -30.75 1.68 16.04

BRIEF-Abeona Announces FDA Grants Rmat Designation To ABO-102 Gene Therapy In MPS Iiia

* ABEONA ANNOUNCES FDA GRANTS RMAT DESIGNATION TO ABO-102 GENE THERAPY IN MPS IIIA

23 Apr 2018

BRIEF-Abeona Therapeutics Receives Orphan Drug Designation In The European Union For ABO-202 Gene Therapy Program In Batten Disease

* ABEONA THERAPEUTICS RECEIVES ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR ABO-202 GENE THERAPY PROGRAM IN BATTEN DISEASE Source text for Eikon: Further company coverage:

20 Apr 2018

Earnings vs. Estimates